ViiV Readies Entry To HIV PrEP Market After Apretude Approval

 
• By Joseph Haas

A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.

FDA approved background, 3D rendering, blue street sign
ViiV will become the second company into HIV PrEP with approval of Apretude

More from New Products

More from Scrip